SEC Form 8-K Summary
Registrant: Priveterra Acquisition Corp., in connection with its proposed business combination with AEON Biopharma, Inc. The report was filed June 15, 2023, under Items 3.01, 8.01, and 9.01. The filing does not present AEON Biopharma’s operating results or financial statements.
Business Context and Reporting Period
Priveterra is a special purpose acquisition company seeking stockholder approval for a business combination with AEON Biopharma. The scheduled June 15, 2023 special meeting was adjourned to June 21, 2023, at 12:00 p.m. Eastern Time, to allow additional time to engage with stockholders.
Financial Metrics and Liquidity
- The filing does not provide revenue, profit, cash flow, margins, debt, cash balances, or other operating financial metrics.
- Nasdaq notified Priveterra that its Market Value of Listed Securities had remained below the $35 million continued-listing requirement for 30 consecutive business days.
- The company received until December 11, 2023, to regain compliance. Its securities could continue trading during this compliance period.
Material Changes Versus the Prior Comparable Period
- No period-to-period financial comparison is provided.
- The material developments were the Nasdaq listing deficiency notice, the adjournment of the special meeting, and supplemental proxy disclosures.
Guidance, Outlook, Risks, and Unusual Items
- To regain Nasdaq compliance, the company’s MVLS must close at or above $35 million for at least 10 consecutive business days during the compliance period.
- If compliance was not restored by December 11, 2023, Nasdaq staff could issue a delisting notice. The company could then appeal to a Nasdaq Hearings Panel.
- Management stated that it intended to monitor MVLS and may consider available options to regain compliance.
- Stockholders could withdraw previously submitted redemption requests before the rescheduled meeting by requesting return of their shares from the transfer agent.
- The filing contains forward-looking statements regarding the business combination and related matters, which are subject to transaction, regulatory, market, financing, redemption, and other risks described in the proxy statement and related SEC filings.
Important Facts for Investors to Verify
- Whether stockholders approved the proposed AEON Biopharma business combination at the rescheduled June 21, 2023 meeting.
- The level of stockholder redemptions and the resulting cash available to the combined company.
- Whether Priveterra regained compliance with Nasdaq’s $35 million MVLS requirement or received a delisting notice.
- The definitive transaction terms, post-closing ownership, financing arrangements, and pro forma capitalization in the proxy statement and related filings.
- AEON Biopharma’s financial results, cash needs, pipeline status, and other operating information, which are not provided in this 8-K.